Rocha Pinheiro Samuel Luca, Lemos Fabian Fellipe Bueno, Marques Hanna Santos, Silva Luz Marcel, de Oliveira Silva Luís Guilherme, Faria Souza Mendes Dos Santos Clara, da Costa Evangelista Karolaine, Calmon Mariana Santos, Sande Loureiro Matheus, Freire de Melo Fabrício
Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Vitória da Conquista 45029-094, Bahia, Brazil.
Campus Vitória da Conquista, Universidade Estadual do Sudoeste da Bahia, Vitória da Conquista 45029-094, Bahia, Brazil.
World J Clin Oncol. 2023 Apr 24;14(4):138-159. doi: 10.5306/wjco.v14.i4.138.
Glioblastoma remains as the most common and aggressive malignant brain tumor, standing with a poor prognosis and treatment prospective. Despite the aggressive standard care, such as surgical resection and chemoradiation, median survival rates are low. In this regard, immunotherapeutic strategies aim to become more attractive for glioblastoma, considering its recent advances and approaches. In this review, we provide an overview of the current status and progress in immunotherapy for glioblastoma, going through the fundamental knowledge on immune targeting to promising strategies, such as Chimeric antigen receptor T-Cell therapy, immune checkpoint inhibitors, cytokine-based treatment, oncolytic virus and vaccine-based techniques. At last, it is discussed innovative methods to overcome diverse challenges, and future perspectives in this area.
胶质母细胞瘤仍然是最常见且侵袭性最强的恶性脑肿瘤，预后和治疗前景不佳。尽管有积极的标准治疗方法，如手术切除和放化疗，但中位生存率仍然很低。在这方面，考虑到免疫治疗的最新进展和方法，免疫治疗策略对胶质母细胞瘤来说变得更具吸引力。在这篇综述中，我们概述了胶质母细胞瘤免疫治疗的现状和进展，从免疫靶向的基础知识到有前景的策略，如嵌合抗原受体T细胞疗法、免疫检查点抑制剂、基于细胞因子的治疗、溶瘤病毒和基于疫苗的技术。最后，讨论了克服各种挑战的创新方法以及该领域的未来前景。
